Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Citizens Jmp

Context Therapeutics (NASDAQ:CNTX - Get Free Report) was upgraded by stock analysts at Citizens Jmp to a "strong-buy" rating in a note issued to investors on Wednesday,Zacks.com reports.

CNTX has been the subject of a number of other research reports. JMP Securities initiated coverage on Context Therapeutics in a report on Wednesday. They set an "outperform" rating and a $4.00 target price for the company. D. Boral Capital initiated coverage on Context Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating and a $9.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $6.00 target price on shares of Context Therapeutics in a research note on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $6.33.

Context Therapeutics Stock Performance

Context Therapeutics stock traded up $0.12 during trading on Wednesday, reaching $1.21. The company had a trading volume of 783,242 shares, compared to its average volume of 342,874. The firm has a market capitalization of $90.75 million, a PE ratio of -1.33 and a beta of 2.10. The firm's 50-day simple moving average is $1.50 and its 200 day simple moving average is $1.93. Context Therapeutics has a 1-year low of $0.89 and a 1-year high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11). Analysts anticipate that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Trading of Context Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in shares of Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company's stock valued at $131,000 after acquiring an additional 25,300 shares during the last quarter. Ally Bridge Group NY LLC raised its stake in Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company's stock worth $3,782,000 after purchasing an additional 1,160,281 shares during the period. Great Point Partners LLC acquired a new position in Context Therapeutics in the 2nd quarter valued at about $14,876,000. Affinity Asset Advisors LLC grew its stake in shares of Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company's stock valued at $3,246,000 after buying an additional 1,290,323 shares during the period. Finally, Blue Owl Capital Holdings LP acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth approximately $10,348,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.